Biomarkers associated with checkpoint inhibitors

Annals of Oncology

Volumn 27, Issue 7, 2016, Pages 1199-1206

  Manson, G ^a   Norwood, J ^a   Marabelle, A ^b   Kohrt, H ^c   Houot, R ^a,d  

^a RENNES UNIVERSITY HOSPITAL   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c Stanford Medicine Children s Health   (United States)

^d INSERM   (France)

Author keywords

Biomarkers; Cancer; Checkpoint inhibitors; Immunotherapy

Indexed keywords

BIOLOGICAL MARKER; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 17; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; INTERLEUKIN 8; IPILIMUMAB; LACTATE DEHYDROGENASE; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TUMOR ANTIGEN; ANTIIDIOTYPIC ANTIBODY; CD274 PROTEIN, HUMAN; CELL CYCLE PROTEIN; CTLA4 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; DRUG APPROVAL; DRUG EFFECT; DRUG INDICATION; DRUG RESPONSE; EOSINOPHIL; GENE EXPRESSION PROFILING; HUMAN; IMMUNE RESPONSE; KIDNEY CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MONOCYTE; MYELOID DERIVED SUPPRESSOR CELL; NEUTROPHIL; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; TUMOR ASSOCIATED LEUKOCYTE; ANTAGONISTS AND INHIBITORS; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; NEOPLASM;

ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; B7-H1 ANTIGEN; BIOMARKERS, TUMOR; CELL CYCLE PROTEINS; CTLA-4 ANTIGEN; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84977071049     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw181     Document Type: Article

References (72)

1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-264.
2. Selby MJ, Engelhardt JJ, Quigley M et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 2013; 1: 32-42.
3. McDermott DF, Atkins MB. PD-1 as a potential target in cancer therapy. Cancer Med 2013; 2: 662-673.
4. Wolchok JD, Neyns B, Linette G et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11: 155-164.
5. Kelderman S, Heemskerk B, van Tinteren H et al. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother 2014; 63: 449-458.
6. Ku GY, Yuan J, Page DB et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting. Cancer 2010; 116: 1767-1775.
7. Delyon J et al. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol 2013; 24: 1697-1703.
8. Berman DM, Wolchok J, Weber J et al. Association of peripheral blood absolute lymphocyte count (ALC) and clinical activity in patients (pts) with advanced melanoma treated with ipilimumab. J Clin Oncol 2009; 27.
9. Di Giacomo AM, Calabrò L, Danielli R et al. Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10mg/kg within an expanded access programme. Cancer Immunol Immunother 2013; 62: 1021-1028.
10. Schindler K, Harmankaya K, Postow M et al. Pretreatment levels of absolute and relative eosinophil count to improve overall survival (OS) in patients with metastatic melanoma under treatment with ipilimumab, an anti CTLA-4 antibody. In ASCO Annual Meeting, 2013.
11. Romano E, Kusio-Kobialka M, Foukas PG et al. Ipilimumab-dependent cellmediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci USA 2015; 112: 6140-6145.
12. Herbst RS, Soria J-C, Kowanetz M et al. Predictive correlates of response to the anti- PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515: 563-567.
13. Powles T, Eder JP, Fine GD et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014; 515: 558-562.
14. Liakou CI et al. CTLA-4 blockade increases IFNgamma-producing CD4+ ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci USA 2008; 105: 14987-14992.
15. Chen H, Liakou CI, Kamat A et al. Anti-CTLA-4 therapy results in higher CD4+ ICOShi T cell frequency and IFN-levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci USA 2009; 106: 2729-2734.
16. Carthon BC, Wolchok JD, Yuan J et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res 2010; 16: 2861-2871.
17. Cha E, Klinger M, Hou Y et al. Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci Transl Med 2014; 6: 238ra70.
18. Kvistborg P, Philips D, Kelderman S et al. Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci Transl Med 2014; 6: 254ra128.
19. Postow MA, Manuel M, Wong P et al. Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma. J Immunother Cancer 2015; 3: 23.
20. Yuan J, Adamow M, Ginsberg BA et al. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci USA 2011; 108: 16723-16728.
21. Attia P. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005; 23: 6043-6053.
22. Sojka DK, Huang Y-H, Fowell DJ. Mechanisms of regulatory T-cell suppression-a diverse arsenal for a moving target. Immunology 2008; 124: 13-22.
23. Weber JS, Hamid O, Chasalow SD et al. Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma. J Immunother 2012; 35: 89-97.
24. Maker AV et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 2005; 12: 1005-1016.
25. Simeone E et al. Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol Immunother 2014; 63: 675-683.
26. Tarhini AA, Edington H, Butterfield LH et al. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One 2014; 9: e87705.
27. Weide B, Di Giacomo AM, Fonsatti E, Zitvogel L. Immunologic correlates in the course of treatment with immunomodulating antibodies. Semin Oncol 2015; 42: 448-458.
28. Pico de Coaña Y, Poschke I, Gentilcore G et al. Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their Arginase1 production. Cancer Immunol Res 2013; 1: 158-162.
29. Martens A, Wistuba-Hamprecht K, Geukes Foppen MH et al. Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Clin Cancer Res 2016, doi:10.1158/1078- 0432.CCR-15-2412
30. Kitano S et al. Computational algorithm-driven evaluation of monocytic myeloidderived suppressor cell frequency for prediction of clinical outcomes. Cancer Immunol Res 2014; 2: 812-821.
31. Hannani D et al. Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res 2015; 25: 208-224.
32. Wilgenhof S et al. Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma. J Immunother 2013; 36: 215-222.
33. Das R, Verma R, Sznol M et al. Combination therapy with anti-CTLA-4 and anti- PD-1 leads to distinct immunologic changes in vivo. J Immunol 2014; 194: 950-959.
34. Hamid O, Schmidt H, Nissan A et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med 2011; 9: 204.
35. Hodi FS, Butler M, Oble DA et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 2008; 105: 3005-3010.
36. Tumeh PC, Harview CL, Yearley JH et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515: 568-571.
37. Beavis PA, Slaney CY, Milenkovski N et al. CD73: a potential biomarker for anti- PD-1 therapy. Oncoimmunology 2015; 4: e1046675.
38. Snyder A, Makarov V, Merghoub T et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014; 371: 2189-2199.
39. Van Allen EM, Miao D, Schilling B et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 2015; 350: 207-211.
40. Rizvi NA, Hellmann MD, Snyder A et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348: 124-128.
41. Le DT, Uram JN, Wang H et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372: 2509-2520.
42. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454.
43. Garon EB, Rizvi NA, Hui R et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372: 2018-2028.
44. Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320-330.
45. Robert C, Schachter J, Long GV et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372: 2521-2532.
46. Postow MA, Cardona DM, Taube JM et al. Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab. J Transl Med 2014; 12: O8.
47. Kefford R, Ribas A, Hamid O et al. Clinical efficacy and correlation with tumor PDL1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. ASCO Annual Meeting J Clin Oncol 2014; 32:5s (Suppl): abstr 3005.
48. Daud A, Ribas A, Robert C et al. Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001. ASCO Meet Abstr 2015; 33: 9005.
49. Carbognin L, Pilotto S, Milella M et al. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS One 2015; 10: e0130142.
50. Ji R-R, Chasalow SD, Wang L et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 2012; 61: 1019-1031.
51. Hugo W, Zaretsky JM, Sun L et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 2016; 165: 35-44.
52. Fu T, He Q, Sharma P. The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy. Cancer Res 2011; 71: 5445-5454.
53. Vonderheide RH, LoRusso PM, Khalil M et al. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin Cancer Res 2010; 16: 3485-3494.
54. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9: 162-174.
55. Diaz-Montero CM, Finke J, Montero AJ. Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications. Semin Oncol 2014; 41: 174-184.
56. Balch CM, Gershenwald JE, Soong S-J et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-6206.
57. Ruffini E, Asioli S, Filosso PL et al. Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. Ann Thorac Surg 2009; 87: 365-371; discussion 371-372.
58. Alexandrov LB, Nik-Zainal S, Wedge DC et al. Signatures of mutational processes in human cancer. Nature 2013; 500: 415-421.
59. Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 2015; 160: 48-61.
60. Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373: 1270-1271.
61. Mbongue JC, Nicholas DA, Torrez TW et al. The role of indoleamine 2, 3- dioxygenase in immune suppression and autoimmunity. Vaccines 2015; 3: 703-729.
62. Jung ID, Lee C-M, Jeong Y-I et al. Differential regulation of indoleamine 2,3- dioxygenase by lipopolysaccharide and interferon gamma in murine bone marrow derived dendritic cells. FEBS Lett 2007; 581: 1449-1456.
63. Robinson CM, Hale PT, Carlin JM. The role of IFN-gamma and TNF-alpharesponsive regulatory elements in the synergistic induction of indoleamine dioxygenase. J Interferon Cytokine Res 2005; 25: 20-30.
64. Michot JM, Bigenwald C, Champiat S et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 2016; 54: 139-148.
65. Schindler K, Harmankaya K, Kuk D et al. Correlation of absolute and relative eosinophil counts with immune-related adverse events in melanoma patients treated with ipilimumab. ASCO Meet Abstr 2014; 32.
66. Callahan MK, Yang A, Tandon S et al. Evaluation of serum IL-17 levels during ipilimumab therapy: correlation with colitis. ASCO Meet Abstr 2011; 29.
67. Shahabi V, Berman D, Chasalow SD et al. Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immunerelated gastrointestinal adverse events. J Transl Med 2013; 11: 75.
68. Berman D, Parker SM, Siegel J et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun 2010; 10: 11.
69. Downey SG et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007; 13: 6681-6688.
70. Tarhini A, Lo E, Minor DR. Releasing the brake on the immune system: ipilimumab in melanoma and other tumors. Cancer Biother Radiopharm 2010; 25: 601-613.
71. Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother 2009; 58: 823-830.
72. Ascierto PA et al. Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med 2014; 12: 116.